Co-Authors
This is a "connection" page, showing publications co-authored by HAGOP M KANTARJIAN and GUILLERMO GARCIA-MANERO.
Connection Strength
52.045
-
Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes. J Clin Oncol. 2013 Jul 10; 31(20):2548-53.
Score: 0.470
-
Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. J Clin Oncol. 2012 Jun 20; 30(18):2204-10.
Score: 0.437
-
The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS? Cancer. 2009 Nov 15; 115(22):5202-9.
Score: 0.368
-
Epigenetics of acute lymphocytic leukemia. Semin Hematol. 2009 Jan; 46(1):24-32.
Score: 0.346
-
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008 Sep 15; 113(6):1351-61.
Score: 0.339
-
A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia. 2008 Mar; 22(3):538-43.
Score: 0.322
-
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2008 Feb 01; 111(3):1060-6.
Score: 0.319
-
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia. Cancer. 2024 Apr 09.
Score: 0.250
-
Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax. Clin Cancer Res. 2024 Apr 01; 30(7):1319-1326.
Score: 0.249
-
Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms. Cancer Med. 2024 Mar; 13(5):e7093.
Score: 0.248
-
Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia. Leukemia. 2024 Feb 28.
Score: 0.248
-
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study. Lancet Haematol. 2024 Mar; 11(3):e186-e195.
Score: 0.246
-
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. Lancet Haematol. 2024 Jan; 11(1):e15-e26.
Score: 0.245
-
Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents. Br J Haematol. 2024 Mar; 204(3):898-909.
Score: 0.242
-
Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. Am J Hematol. 2023 11; 98(11):1711-1720.
Score: 0.239
-
Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia. Br J Haematol. 2023 11; 203(4):581-592.
Score: 0.239
-
Chronic myelogenous leukemia: a review and update of therapeutic strategies. Cancer. 2003 Aug 01; 98(3):437-57.
Score: 0.238
-
Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure. Am J Hematol. 2023 10; 98(10):E281-E284.
Score: 0.238
-
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. J Hematol Oncol. 2023 07 08; 16(1):73.
Score: 0.237
-
Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside. Cancer. 2003 Jun 15; 97(12):3010-6.
Score: 0.236
-
Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome. Blood Adv. 2023 06 13; 7(11):2378-2387.
Score: 0.236
-
Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results. Clin Lymphoma Myeloma Leuk. 2023 10; 23(10):742-748.
Score: 0.235
-
Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol. 2023 Jun; 10(6):e433-e444.
Score: 0.234
-
Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia. J Hematol Oncol. 2023 05 02; 16(1):44.
Score: 0.234
-
Characteristics of patients with myelodysplastic neoplasm and spliceosome mutations. Leukemia. 2023 06; 37(6):1397-1400.
Score: 0.233
-
Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study. Lancet Haematol. 2023 Apr; 10(4):e272-e283.
Score: 0.232
-
Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumours. Br J Haematol. 2023 05; 201(3):e25-e29.
Score: 0.232
-
The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors. Am J Hematol. 2023 04; 98(4):658-665.
Score: 0.230
-
Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia. Cancer. 2023 04 01; 129(7):1017-1029.
Score: 0.230
-
Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. Am J Hematol. 2023 03; 98(3):493-501.
Score: 0.229
-
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. 2022 Nov 16.
Score: 0.227
-
TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions. Cancer Discov. 2022 11 02; 12(11):2516-2529.
Score: 0.226
-
Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 2022 Dec; 9(12):e878-e885.
Score: 0.225
-
Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients. Am J Hematol. 2022 Nov; 97(11):1427-1434.
Score: 0.224
-
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. Lancet Haematol. 2022 Oct; 9(10):e756-e765.
Score: 0.223
-
Low-dose dasatinib 50?mg/day versus standard-dose dasatinib 100?mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis. Am J Hematol. 2022 Nov; 97(11):1413-1418.
Score: 0.223
-
Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS. NEJM Evid. 2022 Oct; 1(10):EVIDoa2200034.
Score: 0.222
-
Real-life incidence of thrombotic events in leukemia patients treated with ponatinib. Am J Hematol. 2022 Sep; 97(9):E350-E352.
Score: 0.221
-
Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10-4 and higher. Am J Hematol. 2022 Sep; 97(9):1135-1141.
Score: 0.220
-
Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol. 2022 11 20; 40(33):3848-3857.
Score: 0.220
-
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Am J Hematol. 2022 08; 97(8):1035-1043.
Score: 0.219
-
Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD. Blood Adv. 2022 05 24; 6(10):3027-3035.
Score: 0.219
-
Prediction of survival with intensive chemotherapy in acute myeloid leukemia. Am J Hematol. 2022 07; 97(7):865-876.
Score: 0.217
-
Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. Am J Hematol. 2022 07; 97(7):856-864.
Score: 0.217
-
Current therapy of chronic myelogenous leukemia. Intern Med. 2002 Apr; 41(4):254-64.
Score: 0.217
-
Time to blur the blast boundaries. Cancer. 2022 04 15; 128(8):1568-1570.
Score: 0.215
-
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. J Hematol Oncol. 2022 01 29; 15(1):12.
Score: 0.214
-
Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. Am J Hematol. 2022 01 01; 97(1):68-78.
Score: 0.211
-
Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm. Blood. 2021 10 14; 138(15):1373-1377.
Score: 0.210
-
The cure of leukemia through the optimist's prism. Cancer. 2022 01 15; 128(2):240-259.
Score: 0.210
-
Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome. Br J Haematol. 2021 11; 195(3):378-387.
Score: 0.207
-
Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2021 Aug; 8(8):e552-e561.
Score: 0.207
-
Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. Cancer. 2021 10 01; 127(19):3552-3565.
Score: 0.206
-
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol. 2021 09 01; 39(25):2768-2778.
Score: 0.205
-
Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2021 08 01; 96(8):914-924.
Score: 0.204
-
Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer. 2021 09 01; 127(17):3113-3124.
Score: 0.203
-
Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS). Am J Hematol. 2021 07 01; 96(7):E246-E249.
Score: 0.203
-
Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia. 2021 05; 35(5):1494-1499.
Score: 0.203
-
Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2021 06 15; 127(12):2025-2038.
Score: 0.202
-
Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood Cancer J. 2021 03 06; 11(3):52.
Score: 0.201
-
Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021 02 22; 11(2):41.
Score: 0.201
-
Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemia. Leuk Res. 2021 02; 101:106511.
Score: 0.200
-
The hyper-CVAD regimen in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2000 Dec; 14(6):1381-96, x-xi.
Score: 0.198
-
Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. Am J Hematol. 2021 02 01; 96(2):E50-E53.
Score: 0.197
-
Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3). Am J Hematol. 2020 12; 95(12):E326-E329.
Score: 0.196
-
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. Blood. 2020 08 06; 136(6):674-683.
Score: 0.193
-
Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020 Jul; 7(7):e523-e533.
Score: 0.192
-
Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2020 11; 20(11):e871-e882.
Score: 0.191
-
Results of a Phase 1/2a dose-escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes. Leuk Lymphoma. 2020 08; 61(8):1943-1953.
Score: 0.189
-
Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. Cancer. 2020 05 15; 126(10):2193-2205.
Score: 0.188
-
Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Adv. 2020 02 11; 4(3):482-495.
Score: 0.187
-
LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents. Leuk Lymphoma. 2020 06; 61(6):1493-1499.
Score: 0.187
-
Long-term results of a phase 2 trial of nilotinib 400?mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia. Cancer. 2020 04 01; 126(7):1448-1459.
Score: 0.187
-
Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia. Cancer. 2020 02 15; 126(4):765-774.
Score: 0.184
-
Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes. Leukemia. 2020 03; 34(3):872-881.
Score: 0.184
-
Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders. Haematologica. 2020 06; 105(6):1567-1574.
Score: 0.182
-
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol. 2019 Sep; 6(9):e480-e488.
Score: 0.180
-
Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy. Leuk Lymphoma. 2019 12; 60(13):3172-3180.
Score: 0.178
-
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. Lancet Haematol. 2019 Jun; 6(6):e317-e327.
Score: 0.177
-
Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2019 08 01; 125(15):2579-2586.
Score: 0.177
-
An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. Lancet Haematol. 2019 Apr; 6(4):e194-e203.
Score: 0.176
-
NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. Blood Adv. 2019 03 26; 3(6):922-933.
Score: 0.176
-
Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome. Cancer. 2019 07 01; 125(13):2233-2241.
Score: 0.175
-
Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia. Cancer. 2019 05 15; 125(10):1665-1673.
Score: 0.174
-
Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome. Hematol Oncol. 2019 Feb; 37(1):96-102.
Score: 0.172
-
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol. 2018 Dec; 5(12):e618-e627.
Score: 0.172
-
A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. Am J Hematol. 2019 01; 94(1):74-79.
Score: 0.172
-
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discov. 2019 03; 9(3):370-383.
Score: 0.171
-
A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. Cancer Med. 2018 11; 7(11):5457-5469.
Score: 0.171
-
Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer. 2018 10 15; 124(20):4044-4055.
Score: 0.170
-
Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation. Leuk Res. 2018 10; 73:78-85.
Score: 0.170
-
Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematol. 2018 Sep; 5(9):e411-e421.
Score: 0.169
-
A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2018 10; 18(10):658-663.e2.
Score: 0.167
-
Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases. Leukemia. 2018 11; 32(11):2512-2518.
Score: 0.165
-
Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. Cancer. 2018 06 15; 124(12):2534-2540.
Score: 0.165
-
Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Leukemia. 2018 05; 32(5):1094-1105.
Score: 0.163
-
Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations. Int J Hematol. 2018 Jun; 107(6):689-695.
Score: 0.163
-
Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial. JAMA Oncol. 2018 Feb 01; 4(2):230-234.
Score: 0.163
-
Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018 02; 19(2):240-248.
Score: 0.162
-
Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. Cancer. 2017 Dec 15; 123(24):4851-4859.
Score: 0.158
-
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. Lancet Oncol. 2017 10; 18(10):1317-1326.
Score: 0.158
-
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood. 2017 09 28; 130(13):1514-1522.
Score: 0.157
-
Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. Am J Hematol. 2017 Sep; 92(9):924-928.
Score: 0.157
-
A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer. 2017 Nov 15; 123(22):4430-4439.
Score: 0.156
-
An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes. Am J Hematol. 2017 Jul; 92(7):674-682.
Score: 0.155
-
Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. Am J Hematol. 2017 Jul; 92(7):599-606.
Score: 0.155
-
A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia. 2017 07; 31(7):1659.
Score: 0.153
-
Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents. Am J Hematol. 2017 Apr; 92(4):351-358.
Score: 0.152
-
Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia. Leuk Lymphoma. 2017 09; 58(9):1-6.
Score: 0.152
-
Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes. Cancer. 2017 May 15; 123(6):994-1002.
Score: 0.151
-
A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia. 2017 02; 31(2):318-324.
Score: 0.149
-
Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer. 2017 Feb 15; 123(4):629-637.
Score: 0.149
-
Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Cancer. 2017 02 01; 123(3):426-435.
Score: 0.148
-
Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer. 2017 01 01; 123(2):294-302.
Score: 0.147
-
Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2016 Dec 01; 122(23):3650-3656.
Score: 0.146
-
TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer. 2016 Nov 15; 122(22):3484-3491.
Score: 0.146
-
Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-M?nster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. Am J Hematol. 2016 08; 91(8):819-23.
Score: 0.146
-
Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget. 2016 Mar 22; 7(12):14172-87.
Score: 0.143
-
Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. Cancer. 2016 06 15; 122(12):1871-9.
Score: 0.143
-
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncol. 2016 Apr; 17(4):496-508.
Score: 0.142
-
Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Am J Hematol. 2016 Feb; 91(2):227-32.
Score: 0.141
-
Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia. Future Oncol. 2016 Feb; 12(3):293-302.
Score: 0.141
-
Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions. Curr Oncol Rep. 2016 Jan; 18(1):4.
Score: 0.141
-
Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2016 Feb; 172(3):392-400.
Score: 0.139
-
Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leuk Res. 2015 Dec; 39(12):1367-74.
Score: 0.139
-
Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015 Dec 01; 121(23):4158-64.
Score: 0.137
-
Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol. 2015 Aug; 90(8):732-6.
Score: 0.137
-
IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression. Leukemia. 2016 Apr; 30(4):980-4.
Score: 0.137
-
Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival. Clin Lymphoma Myeloma Leuk. 2015 Sep; 15(9):556-62.
Score: 0.135
-
Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies. Invest New Drugs. 2015 Aug; 33(4):870-80.
Score: 0.134
-
Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Cancer. 2015 Jul 15; 121(14):2375-82.
Score: 0.133
-
Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up. Leuk Res. 2015 May; 39(5):520-4.
Score: 0.133
-
Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody. Am J Hematol. 2015 Mar; 90(3):193-6.
Score: 0.132
-
Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. Lancet Haematol. 2015 Jan; 2(1):e12-20.
Score: 0.131
-
A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes. Clin Cancer Res. 2015 Mar 01; 21(5):985-94.
Score: 0.131
-
Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer. 2015 Feb 15; 121(4):556-61.
Score: 0.129
-
Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014 Nov; 167(3):356-65.
Score: 0.127
-
Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. Am J Hematol. 2014 Oct; 89(10):964-8.
Score: 0.127
-
Augmented Berlin-Frankfurt-M?nster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer. 2014 Dec 01; 120(23):3660-8.
Score: 0.127
-
The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes. Leuk Lymphoma. 2015 Feb; 56(2):390-4.
Score: 0.127
-
Acute myeloid leukemia with t(10;11): a pathological entity with distinct clinical presentation. Clin Lymphoma Myeloma Leuk. 2015 Jan; 15(1):47-51.
Score: 0.126
-
Integrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution. Br J Haematol. 2014 Sep; 166(5):646-59.
Score: 0.126
-
Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes. Am J Hematol. 2014 May; 89(5):509-16.
Score: 0.124
-
Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia. 2014 Jul; 28(7):1543-5.
Score: 0.123
-
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014 Jun; 28(6):1280-8.
Score: 0.122
-
Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):93-7.
Score: 0.121
-
A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):223-30.
Score: 0.121
-
Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. Blood. 2013 Oct 17; 122(16):2807-11; quiz 2920.
Score: 0.119
-
Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. Am J Hematol. 2013 Oct; 88(10):831-7.
Score: 0.119
-
Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):592-6.
Score: 0.118
-
Toll-like receptor alterations in myelodysplastic syndrome. Leukemia. 2013 Sep; 27(9):1832-40.
Score: 0.118
-
Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):559-67.
Score: 0.118
-
Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia. 2013 Oct; 27(10):2081-3.
Score: 0.118
-
Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells. Leukemia. 2013 Nov; 27(11):2177-86.
Score: 0.116
-
Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):131-8.
Score: 0.114
-
FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol. 2013 Jan; 88(1):56-9.
Score: 0.113
-
Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Lancet Oncol. 2012 Nov; 13(11):1096-104.
Score: 0.113
-
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2012 Aug; 12(4):244-51.
Score: 0.109
-
EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. Blood. 2012 May 10; 119(19):4524-6.
Score: 0.108
-
Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy. Cancer. 2012 Jun 15; 118(12):3116-22.
Score: 0.108
-
Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer. 2012 Sep 15; 118(18):4471-7.
Score: 0.107
-
Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia. Am J Hematol. 2012 Mar; 87(3):317-8.
Score: 0.107
-
Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012 Mar 01; 119(9):1981-7.
Score: 0.107
-
A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias. Cancer. 2012 Jul 15; 118(14):3556-64.
Score: 0.106
-
Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. Am J Hematol. 2012 Jan; 87(1):127-9.
Score: 0.106
-
Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. Cancer. 2012 May 15; 118(10):2665-73.
Score: 0.105
-
Association of anemia and cognitive dysfunction in patients with acute myelogenous leukemia and myelodysplastic syndrome. Am J Hematol. 2011 Nov; 86(11):950-2.
Score: 0.104
-
Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood. 2011 Oct 27; 118(17):4690-3.
Score: 0.104
-
The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint? Clin Lymphoma Myeloma Leuk. 2011 Oct; 11(5):421-6.
Score: 0.104
-
A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer. 2012 Feb 01; 118(3):722-8.
Score: 0.103
-
Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. J Clin Oncol. 2011 Aug 10; 29(23):3173-8.
Score: 0.103
-
Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol. 2011 Jun 20; 29(18):2521-7.
Score: 0.102
-
Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib. Cancer. 2011 Nov 15; 117(22):5085-93.
Score: 0.102
-
Prediction model for mortality after intracranial hemorrhage in patients with leukemia. Am J Hematol. 2011 Jul; 86(7):546-9.
Score: 0.102
-
Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia. Invest New Drugs. 2012 Jun; 30(3):1107-15.
Score: 0.101
-
Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications. Clin Lymphoma Myeloma Leuk. 2011 Apr; 11(2):237-41.
Score: 0.101
-
The search for better prognostic models in myelodysplastic syndromes. Curr Hematol Malig Rep. 2011 Mar; 6(1):13-21.
Score: 0.101
-
Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA. Am J Hematol. 2011 Feb; 86(2):237-8.
Score: 0.100
-
Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):54-9.
Score: 0.100
-
Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study. Cancer. 2010 Nov 15; 116(22):5272-8.
Score: 0.099
-
Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. Blood. 2010 Dec 23; 116(26):5818-23; quiz 6153.
Score: 0.098
-
Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer. 2010 Dec 15; 116(24):5568-74.
Score: 0.097
-
Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer. 2010 Aug 15; 116(16):3830-4.
Score: 0.097
-
Current and future management options for myelodysplastic syndromes. Drugs. 2010 Jul 30; 70(11):1381-94.
Score: 0.097
-
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010 Nov 25; 116(22):4422-9.
Score: 0.097
-
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010 Aug 20; 28(24):3880-9.
Score: 0.097
-
Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood. 2010 Oct 28; 116(17):3163-70.
Score: 0.096
-
Characteristics of pericardial effusions in patients with leukemia. Cancer. 2010 May 15; 116(10):2366-71.
Score: 0.095
-
First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood. 2010 Sep 23; 116(12):2070-7.
Score: 0.095
-
Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer. 2010 May 01; 116(9):2174-9.
Score: 0.095
-
A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. Br J Haematol. 2010 Jul; 150(1):72-82.
Score: 0.095
-
Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol. 2010 Jun 01; 28(16):2755-60.
Score: 0.095
-
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010 Apr 10; 28(11):1856-62.
Score: 0.094
-
Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias. Genes Chromosomes Cancer. 2010 Feb; 49(2):182-91.
Score: 0.093
-
Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission. Leuk Lymphoma. 2010 Mar; 51(3):475-80.
Score: 0.093
-
Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer. 2009 Dec 15; 115(24):5746-51.
Score: 0.093
-
Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. J Clin Oncol. 2010 Jan 10; 28(2):285-91.
Score: 0.092
-
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol. 2009 Oct 01; 27(28):4760-6.
Score: 0.091
-
Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol. 2009 Aug 10; 27(23):3842-8.
Score: 0.089
-
Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy. Oncologist. 2009 May; 14(5):489-96.
Score: 0.088
-
Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia. Blood. 2009 Feb 26; 113(9):1892-8.
Score: 0.086
-
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009 Feb 01; 27(4):504-10.
Score: 0.086
-
Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer. 2008 Dec 01; 113(11):3186-91.
Score: 0.086
-
Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer. 2008 Oct 01; 113(7 Suppl):1933-52.
Score: 0.085
-
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood. 2009 Jun 18; 113(25):6330-7.
Score: 0.084
-
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2008 Sep 01; 112(5):1638-45.
Score: 0.083
-
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res. 2008 Jun 15; 14(12):3906-15.
Score: 0.083
-
A pilot pharmacokinetic study of oral azacitidine. Leukemia. 2008 Sep; 22(9):1680-4.
Score: 0.083
-
Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer. 2008 Jun; 112(11):2341-51.
Score: 0.083
-
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood. 2008 Aug 15; 112(4):981-9.
Score: 0.083
-
Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer. 2008 Feb 15; 112(4):837-45.
Score: 0.081
-
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007 Oct 01; 110(7):2302-8.
Score: 0.078
-
Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer. 2007 Mar 15; 109(6):1133-7.
Score: 0.076
-
A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. Leuk Lymphoma. 2007 Feb; 48(2):283-9.
Score: 0.076
-
Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer. 2007 Jan 15; 109(2):265-73.
Score: 0.076
-
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer. 2007 Jan 15; 109(2):248-55.
Score: 0.076
-
The role of decitabine in the treatment of myelodysplastic syndromes. Expert Opin Pharmacother. 2007 Jan; 8(1):65-73.
Score: 0.075
-
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007 Jan 01; 109(1):52-7.
Score: 0.073
-
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006 Nov 15; 108(10):3271-9.
Score: 0.073
-
Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse. Br J Haematol. 2006 Jul; 134(1):58-60.
Score: 0.073
-
Granulocyte colony stimulating factor administration associated with cerebral hemorrhage in acute promyelocytic leukemia. Leukemia. 2006 Aug; 20(8):1452-3.
Score: 0.072
-
Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood. 2006 Sep 15; 108(6):1835-40.
Score: 0.072
-
Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer. 2006 May 01; 106(9):1974-84.
Score: 0.072
-
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006 Apr 01; 106(7):1569-80.
Score: 0.072
-
Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer. 2006 Mar 15; 106(6):1306-15.
Score: 0.071
-
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006 Mar 01; 106(5):1090-8.
Score: 0.071
-
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood. 2006 Jul 01; 108(1):45-51.
Score: 0.070
-
Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer. 2006 Jan 01; 106(1):120-7.
Score: 0.070
-
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006 May 01; 107(9):3469-73.
Score: 0.070
-
Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia. Clin Cancer Res. 2005 Nov 01; 11(21):7817-24.
Score: 0.070
-
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood. 2006 Feb 01; 107(3):880-4.
Score: 0.069
-
Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer. 2005 Aug 01; 104(3):547-54.
Score: 0.068
-
Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience. Cancer. 2005 May 15; 103(10):2099-108.
Score: 0.067
-
Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol. 2005 Jun 10; 23(17):3948-56.
Score: 0.067
-
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res. 2005 May 01; 11(9):3425-32.
Score: 0.067
-
Protein expression of a triad of frequently methylated genes, p73, p57Kip2, and p15, has prognostic value in adult acute lymphocytic leukemia independently of its methylation status. J Clin Oncol. 2005 Jun 10; 23(17):3932-9.
Score: 0.067
-
Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes. J Clin Oncol. 2005 Apr 20; 23(12):2805-12.
Score: 0.066
-
Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid. Leuk Res. 2005 Jul; 29(7):739-48.
Score: 0.066
-
Aberrant DNA methylation of a cell cycle regulatory pathway composed of P73, P15 and P57KIP2 is a rare event in children with acute lymphocytic leukemia. Leuk Res. 2005 Aug; 29(8):881-5.
Score: 0.066
-
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood. 2005 Feb 01; 105(3):940-7.
Score: 0.065
-
Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies. Leuk Res. 2004 Sep; 28(9):991-4.
Score: 0.064
-
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood. 2004 Oct 01; 104(7):1979-88.
Score: 0.063
-
Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature. Leuk Res. 2004 Jun; 28(6):657-60.
Score: 0.063
-
Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res. 2004 May 15; 10(10):3371-6.
Score: 0.063
-
A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia. Clin Cancer Res. 2004 May 01; 10(9):2908-17.
Score: 0.063
-
Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study. Haematologica. 2024 Apr 04.
Score: 0.062
-
Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2024 Apr; 11(4):e287-e298.
Score: 0.062
-
Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia. Cancer. 2004 Apr 01; 100(7):1449-58.
Score: 0.062
-
Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol. 2004 Apr 01; 22(7):1287-92.
Score: 0.062
-
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL. Blood. 2024 Mar 29.
Score: 0.062
-
Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm. Blood Adv. 2024 Mar 21.
Score: 0.062
-
Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study. Lancet Haematol. 2024 Apr; 11(4):e276-e286.
Score: 0.062
-
Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Adv. 2024 Feb 27; 8(4):927-935.
Score: 0.062
-
Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups. Am J Hematol. 2024 Apr; 99(4):792-796.
Score: 0.062
-
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML. J Clin Oncol. 2024 Jan 26; JCO2301911.
Score: 0.062
-
Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 1):68-75.
Score: 0.061
-
Myeloid lineage switch in KMT2A-rearranged acute lymphoblastic leukemia treated with lymphoid lineagedirected therapies. Haematologica. 2024 Jan 01; 109(1):293-297.
Score: 0.061
-
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. 2004 Apr 15; 103(8):2873-8.
Score: 0.061
-
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer. 2003 Dec 15; 98(12):2636-42.
Score: 0.061
-
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL. medRxiv. 2023 Dec 09.
Score: 0.061
-
Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia. Blood. 2023 11 09; 142(19):1647-1657.
Score: 0.061
-
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004 Mar 01; 103(5):1635-40.
Score: 0.061
-
The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia. Ther Adv Hematol. 2023; 14:20406207231205429.
Score: 0.060
-
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004 Jun 15; 103(12):4396-407.
Score: 0.060
-
Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase. Cancer. 2003 Oct 01; 98(7):1430-7.
Score: 0.060
-
Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept. Front Immunol. 2023; 14:1249511.
Score: 0.060
-
Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents. Blood Cancer J. 2023 09 21; 13(1):148.
Score: 0.060
-
Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 2003 Sep 15; 98(6):1105-13.
Score: 0.060
-
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results. J Clin Oncol. 2023 11 01; 41(31):4893-4904.
Score: 0.060
-
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. Am J Hematol. 2023 Nov; 98(11):1780-1790.
Score: 0.060
-
Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). Haematologica. 2023 09 01; 108(9):2331-2342.
Score: 0.060
-
Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer. 2003 Sep 01; 98(5):888-93.
Score: 0.060
-
Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results. Clin Lymphoma Myeloma Leuk. 2023 11; 23(11):e369-e378.
Score: 0.060
-
Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer. 2003 Aug 01; 98(3):522-8.
Score: 0.059
-
Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity. Blood Adv. 2023 07 11; 7(13):3284-3296.
Score: 0.059
-
A Phase Ib/II Study of Ivosidenib with Venetoclax ? Azacitidine in IDH1-Mutated Myeloid Malignancies. Blood Cancer Discov. 2023 07 05; 4(4):276-293.
Score: 0.059
-
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. Blood Cancer J. 2023 06 29; 13(1):101.
Score: 0.059
-
Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation. Am J Hematol. 2023 09; 98(9):1383-1393.
Score: 0.059
-
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003 Oct 01; 102(7):2379-86.
Score: 0.059
-
Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AML. Leuk Res. 2003 Jun; 27(6):475-9.
Score: 0.059
-
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer. 2003 Jun 01; 97(11):2760-6.
Score: 0.059
-
Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 2003 May 01; 97(9):2225-8.
Score: 0.058
-
Targeting MCL1-driven anti-apoptotic pathways to overcome hypomethylating agent resistance in RAS -mutated chronic myelomonocytic leukemia. bioRxiv. 2023 Apr 08.
Score: 0.058
-
Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. Blood Adv. 2023 03 28; 7(6):933-942.
Score: 0.058
-
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. J Clin Oncol. 2003 Mar 15; 21(6):1050-6.
Score: 0.058
-
Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood. 2003 Jul 01; 102(1):83-6.
Score: 0.058
-
Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation. Cancer. 2023 06 15; 129(12):1856-1865.
Score: 0.058
-
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. J Clin Oncol. 2023 05 20; 41(15):2815-2826.
Score: 0.058
-
Association between bariatric surgery and outcomes in chronic myeloid leukemia. Cancer. 2023 06 15; 129(12):1866-1872.
Score: 0.058
-
Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood. 2003 May 15; 101(10):4131-6.
Score: 0.058
-
Aberrant DNA methylation in pediatric patients with acute lymphocytic leukemia. Cancer. 2003 Feb 01; 97(3):695-702.
Score: 0.057
-
Biologic features and clinical outcomes in newly diagnosed myelodysplastic syndrome with KMT2A rearrangements. Am J Hematol. 2023 04; 98(4):E91-E94.
Score: 0.057
-
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood. 2003 May 15; 101(10):3794-800.
Score: 0.057
-
A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia. Cancer. 2023 02 15; 129(4):560-568.
Score: 0.057
-
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms. Blood. 2022 10 20; 140(16):1753-1763.
Score: 0.056
-
Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes. Am J Hematol. 2022 Dec; 97(12):1599-1606.
Score: 0.056
-
Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment. Am J Hematol. 2022 Nov; 97(11):1443-1452.
Score: 0.056
-
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood. 2003 Jan 15; 101(2):473-5.
Score: 0.056
-
Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood. 2002 Sep 01; 100(5):1590-5.
Score: 0.056
-
A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes. Haematologica. 2002 Aug; 87(8):804-7.
Score: 0.055
-
High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance. Leukemia. 2022 09; 36(9):2306-2316.
Score: 0.055
-
High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv. 2022 07 12; 6(13):4006-4014.
Score: 0.055
-
Impact of SF3B1 mutation in myelofibrosis. Leuk Lymphoma. 2022 11; 63(11):2701-2705.
Score: 0.055
-
Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia. Clin Cancer Res. 2002 Jul; 8(7):2134-41.
Score: 0.055
-
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res. 2002 Jul; 8(7):2167-76.
Score: 0.055
-
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res. 2002 Jul; 8(7):2177-87.
Score: 0.055
-
DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin Cancer Res. 2002 Jul; 8(7):2217-24.
Score: 0.055
-
Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Am J Hematol. 2023 01; 98(1):E11-E14.
Score: 0.055
-
Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood. 2002 May 15; 99(10):3547-53.
Score: 0.055
-
Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer J. 2022 05 02; 12(5):77.
Score: 0.055
-
Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematol. 2022 May; 9(5):e350-e360.
Score: 0.055
-
Correction: Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. Leukemia. 2022 May; 36(5):1448.
Score: 0.055
-
Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. Am J Hematol. 2022 07; 97(7):885-894.
Score: 0.055
-
Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study. Cancer. 2022 07 15; 128(14):2736-2745.
Score: 0.054
-
Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer. 2002 Apr 01; 94(7):2024-32.
Score: 0.054
-
Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. Leukemia. 2022 05; 36(5):1253-1260.
Score: 0.054
-
Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification. Am J Hematol. 2022 03 01; 97(3):329-337.
Score: 0.053
-
Correction to: Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia. 2022 Jan; 36(1):298.
Score: 0.053
-
Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience. Blood Adv. 2021 12 14; 5(23):5415-5419.
Score: 0.053
-
Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia. Blood. 2021 11 04; 138(18):1733-1739.
Score: 0.053
-
Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy. Leuk Lymphoma. 2022 03; 63(3):672-675.
Score: 0.053
-
Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer J. 2021 09 29; 11(9):162.
Score: 0.052
-
Clinical and molecular characterization of myeloid sarcoma without medullary leukemia. Leuk Lymphoma. 2021 12; 62(14):3402-3410.
Score: 0.052
-
Phase II study of single-agent nivolumab in patients with myelofibrosis. Ann Hematol. 2021 Dec; 100(12):2957-2960.
Score: 0.052
-
A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica. 2021 08 01; 106(8):2121-2130.
Score: 0.052
-
Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy. Cancer. 2021 10 01; 127(19):3541-3551.
Score: 0.051
-
Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2021 09 15; 127(18):3381-3389.
Score: 0.051
-
Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia. 2022 01; 36(1):257-262.
Score: 0.051
-
Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. Nat Commun. 2021 05 10; 12(1):2607.
Score: 0.051
-
Author Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2021 May 10; 12(1):2823.
Score: 0.051
-
Immunotherapy in Acute Myeloid Leukemia: Where We Stand. Front Oncol. 2021; 11:656218.
Score: 0.051
-
Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Adv. 2021 04 27; 5(8):2173-2183.
Score: 0.051
-
Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv. 2021 04 13; 5(7):1876-1883.
Score: 0.051
-
Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. Cancer. 2021 08 01; 127(15):2641-2647.
Score: 0.051
-
Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer. 2021 08 01; 127(15):2648-2656.
Score: 0.051
-
Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine. Am J Hematol. 2021 05 01; 96(5):589-598.
Score: 0.050
-
Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. 2021 03 01; 106(3):894-898.
Score: 0.050
-
Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol. 2021 Feb 23; 14(1):34.
Score: 0.050
-
Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. Front Oncol. 2020; 10:582213.
Score: 0.050
-
Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications. Front Immunol. 2020; 11:590494.
Score: 0.050
-
Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. Cancer. 2021 06 01; 127(11):1894-1900.
Score: 0.050
-
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes. J Clin Oncol. 2021 05 10; 39(14):1584-1594.
Score: 0.050
-
Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia. Invest New Drugs. 2001; 19(1):13-20.
Score: 0.050
-
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. Am J Hematol. 2021 03 01; 96(3):282-291.
Score: 0.050
-
Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience. Leuk Lymphoma. 2021 04; 62(4):909-917.
Score: 0.049
-
Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Discov. 2021 03; 2(2):125-134.
Score: 0.049
-
Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Adv. 2020 11 24; 4(22):5681-5689.
Score: 0.049
-
Publisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2020 Nov 19; 11(1):5996.
Score: 0.049
-
Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. Cancer. 2021 02 01; 127(3):381-390.
Score: 0.049
-
Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2020 10 21; 11(1):5327.
Score: 0.049
-
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol. 2020 10 08; 13(1):132.
Score: 0.049
-
Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis. Leuk Lymphoma. 2021 01; 62(1):224-228.
Score: 0.049
-
Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations. Am J Hematol. 2020 11; 95(11):E313-E315.
Score: 0.049
-
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020 Oct; 7(10):e724-e736.
Score: 0.049
-
Germline DNMT3A mutation in familial acute myeloid leukaemia. Epigenetics. 2021 05; 16(5):567-576.
Score: 0.049
-
Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. Am J Hematol. 2020 11; 95(11):1288-1295.
Score: 0.048
-
Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. Leuk Lymphoma. 2020 12; 61(13):3120-3127.
Score: 0.048
-
The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia. Am J Hematol. 2020 Oct; 95(10):1127-1134.
Score: 0.048
-
Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. Leuk Lymphoma. 2020 12; 61(12):2811-2820.
Score: 0.048
-
The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. Leukemia. 2021 03; 35(3):691-700.
Score: 0.048
-
Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia. 2020 11; 34(11):2914-2924.
Score: 0.048
-
Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL. Blood Cancer J. 2020 05 26; 10(5):61.
Score: 0.048
-
Treating Leukemia in the Time of COVID-19. Acta Haematol. 2021; 144(2):132-145.
Score: 0.048
-
Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype. Blood Cancer J. 2020 05 04; 10(5):47.
Score: 0.048
-
Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. Blood Adv. 2020 04 28; 4(8):1670-1677.
Score: 0.047
-
Clinical value of event-free survival in acute myeloid leukemia. Blood Adv. 2020 04 28; 4(8):1690-1699.
Score: 0.047
-
Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. Am J Hematol. 2020 07; 95(7):734-739.
Score: 0.047
-
Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1. Mod Pathol. 2020 09; 33(9):1678-1689.
Score: 0.047
-
Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. Am J Hematol. 2020 06; 95(6):612-622.
Score: 0.047
-
Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities. Clin Lymphoma Myeloma Leuk. 2020 09; 20(9):e597-e605.
Score: 0.047
-
A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia. 2020 09; 34(9):2489-2492.
Score: 0.047
-
t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm? Ann Hematol. 2020 Mar; 99(3):487-500.
Score: 0.047
-
Long-term results of frontline dasatinib in chronic myeloid leukemia. Cancer. 2020 04 01; 126(7):1502-1511.
Score: 0.047
-
The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol. 2020 02; 95(2):144-150.
Score: 0.046
-
Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. Am J Hematol. 2019 12; 94(12):1388-1395.
Score: 0.046
-
Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States. Cancer Med. 2019 11; 8(15):6559-6565.
Score: 0.045
-
Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation. Am J Hematol. 2020 02; 95(2):227-229.
Score: 0.045
-
Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. Cancer. 2019 Nov 01; 125(21):3755-3766.
Score: 0.045
-
Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. Am J Hematol. 2019 09; 94(9):984-991.
Score: 0.045
-
Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia. Cancer. 2019 09 15; 125(18):3219-3224.
Score: 0.045
-
DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease. Am J Hematol. 2019 07; 94(7):757-766.
Score: 0.044
-
Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts. Am J Hematol. 2019 07; 94(7):E188-E190.
Score: 0.044
-
Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv. 2019 03 26; 3(6):851-861.
Score: 0.044
-
Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Int J Hematol. 2019 May; 109(5):545-552.
Score: 0.044
-
Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia. Cancer. 2019 06 01; 125(11):1855-1866.
Score: 0.044
-
Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia? Blood Cancer J. 2019 01 16; 9(2):7.
Score: 0.043
-
Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. Nat Commun. 2019 01 16; 10(1):244.
Score: 0.043
-
Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. J Hematol Oncol. 2019 01 03; 12(1):1.
Score: 0.043
-
New Tool for Monitoring Molecular Response in Patients With Chronic Myeloid Leukemia. Appl Immunohistochem Mol Morphol. 2019 01; 27(1):33-39.
Score: 0.043
-
Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2019 03; 19(3):142-148.e1.
Score: 0.043
-
Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol. 2019 Jan; 6(1):e29-e37.
Score: 0.043
-
Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes. Cancer. 2019 04 01; 125(7):1091-1100.
Score: 0.043
-
The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019 05 01; 125(9):1470-1481.
Score: 0.043
-
PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy. Cell Stem Cell. 2018 11 01; 23(5):700-713.e6.
Score: 0.043
-
Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer. 2018 11 01; 124(21):4192-4201.
Score: 0.043
-
Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R. Am J Hematol. 2018 10; 93(10):1245-1253.
Score: 0.043
-
Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable. Blood. 2018 11 08; 132(19):2100-2103.
Score: 0.042
-
Prognostic significance of hyperdiploidy in adult acute myeloid leukemia. Am J Hematol. 2018 11; 93(11):E357-E360.
Score: 0.042
-
Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS. Leuk Res. 2018 10; 73:51-57.
Score: 0.042
-
A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 10 18; 132(16):1664-1674.
Score: 0.042
-
Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia. Am J Hematol. 2018 09; 93(9):1136-1141.
Score: 0.042
-
Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. Blood Adv. 2018 08 14; 2(15):1807-1816.
Score: 0.042
-
Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nat Commun. 2018 07 10; 9(1):2670.
Score: 0.042
-
Response kinetics and factors predicting survival in core-binding factor leukemia. Leukemia. 2018 12; 32(12):2698-2701.
Score: 0.042
-
Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations. Am J Surg Pathol. 2018 06; 42(6):799-806.
Score: 0.042
-
MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma. 2019 01; 60(1):37-48.
Score: 0.041
-
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol. 2018 06 20; 36(18):1788-1797.
Score: 0.041
-
Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. Ann Hematol. 2018 Jul; 97(7):1183-1191.
Score: 0.041
-
Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial. Lancet Haematol. 2018 Apr; 5(4):e136-e146.
Score: 0.041
-
Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome. Mod Pathol. 2018 07; 31(7):1141-1154.
Score: 0.041
-
Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood. 2018 04 19; 131(16):1820-1832.
Score: 0.041
-
Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia. Leuk Lymphoma. 2018 09; 59(9):2238-2241.
Score: 0.041
-
Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget. 2018 Feb 09; 9(11):9714-9727.
Score: 0.040
-
Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice. Adv Exp Med Biol. 2018; 995:97-116.
Score: 0.040
-
Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. Am J Hematol. 2018 03; 93(3):371-374.
Score: 0.040
-
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018 03; 93(3):401-407.
Score: 0.040
-
Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. Cancer. 2018 03 15; 124(6):1160-1168.
Score: 0.040
-
Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care. Blood Cancer J. 2017 12 14; 7(12):644.
Score: 0.040
-
A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. Am J Hematol. 2018 02; 93(2):277-285.
Score: 0.040
-
Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol. 2018 01; 93(1):84-90.
Score: 0.040
-
Myeloid/lymphoid neoplasms with FGFR1 rearrangement. Leuk Lymphoma. 2018 07; 59(7):1672-1676.
Score: 0.040
-
Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leuk Lymphoma. 2018 06; 59(6):1312-1322.
Score: 0.040
-
Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia. J Cutan Pathol. 2017 Dec; 44(12):1075-1079.
Score: 0.040
-
Clinical outcomes in adult patients with aplastic anemia: A single institution experience. Am J Hematol. 2017 Dec; 92(12):1295-1302.
Score: 0.040
-
Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse. Leukemia. 2018 01; 32(1):241-244.
Score: 0.040
-
Time to response and survival in hypomethylating agent-treated acute myeloid leukemia. Leuk Lymphoma. 2018 04; 59(4):1012-1015.
Score: 0.039
-
Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment. Blood. 2017 11 09; 130(19):2084-2091.
Score: 0.039
-
Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. Clin Lymphoma Myeloma Leuk. 2017 Dec; 17(12):897-901.
Score: 0.039
-
Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer. 2017 Nov 15; 123(22):4391-4402.
Score: 0.039
-
Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. Haematologica. 2017 10; 102(10):1709-1717.
Score: 0.039
-
Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Adv. 2017 Jul 25; 1(17):1312-1323.
Score: 0.039
-
A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2018 04; 59(4):813-820.
Score: 0.039
-
The emerging role of immune checkpoint based approaches in AML and MDS. Leuk Lymphoma. 2018 04; 59(4):790-802.
Score: 0.039
-
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma. Cancer Cell. 2017 07 10; 32(1):88-100.e6.
Score: 0.039
-
Copy number alterations detected as clonal hematopoiesis of indeterminate potential. Blood Adv. 2017 Jun 27; 1(15):1031-1036.
Score: 0.039
-
TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. Cancer. 2017 Oct 01; 123(19):3717-3724.
Score: 0.039
-
Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. Am J Hematol. 2017 Sep; 92(9):845-850.
Score: 0.039
-
Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. Am J Hematol. 2017 06; 92(6):E114-E117.
Score: 0.038
-
Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer. 2017 Aug 15; 123(16):3050-3060.
Score: 0.038
-
More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood. 2017 05 04; 129(18):2584-2587.
Score: 0.038
-
Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. Am J Hematol. 2017 Mar; 92(3):238-243.
Score: 0.038
-
Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission. Am J Hematol. 2017 Mar; 92(3):279-285.
Score: 0.038
-
Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017 03 09; 129(10):1275-1283.
Score: 0.038
-
Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. Am J Hematol. 2017 Jan; 92(1):7-11.
Score: 0.038
-
Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. Blood. 2017 02 02; 129(5):572-581.
Score: 0.037
-
Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol. 2017 01; 18(1):100-111.
Score: 0.037
-
Clinical characteristics of Philadelphia positive T-cell lymphoid leukemias-(De novo and blast phase CML). Am J Hematol. 2017 Jan; 92(1):E3-E4.
Score: 0.037
-
Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship. Cancer. 2017 02 15; 123(4):609-616.
Score: 0.037
-
KIR gene haplotype: an independent predictor of clinical outcome in MDS patients. Blood. 2016 12 15; 128(24):2819-2823.
Score: 0.037
-
Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer. 2017 02 01; 123(3):459-467.
Score: 0.037
-
Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy. Am J Hematol. 2016 12; 91(12):1221-1226.
Score: 0.037
-
Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. Blood. 2016 10 20; 128(16):2096-2097.
Score: 0.037
-
Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. Clin Lymphoma Myeloma Leuk. 2016 11; 16(11):616-624.
Score: 0.037
-
Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2016 Dec 15; 122(24):3812-3820.
Score: 0.037
-
A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. Cancer. 2016 Nov 15; 122(21):3336-3343.
Score: 0.037
-
Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study. Leuk Lymphoma. 2017 04; 58(4):866-871.
Score: 0.037
-
Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis. Leuk Res. 2016 09; 48:1-5.
Score: 0.036
-
Time-dependent changes in mortality and transformation risk in MDS. Blood. 2016 08 18; 128(7):902-10.
Score: 0.036
-
Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes. Cancer. 2016 09 15; 122(18):2857-66.
Score: 0.036
-
Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2016 07 28; 128(4):504-7.
Score: 0.036
-
Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis. Haematologica. 2016 08; 101(8):e324-7.
Score: 0.036
-
Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup. Cancer Genet. 2016 05; 209(5):205-14.
Score: 0.036
-
The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure. Haematologica. 2016 06; 101(6):e224-7.
Score: 0.036
-
Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML). Clin Lymphoma Myeloma Leuk. 2016 Apr; 16(4):213-222.e2.
Score: 0.035
-
CD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast count. Leuk Lymphoma. 2016 08; 57(8):1965-8.
Score: 0.035
-
Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents. Leuk Res. 2016 Feb; 41:43-7.
Score: 0.035
-
Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):163-8.e1-2.
Score: 0.035
-
Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. Leukemia. 2016 Mar; 30(3):649-57.
Score: 0.035
-
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015 Nov; 16(15):1547-1555.
Score: 0.035
-
A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia. 2016 Feb; 30(2):268-73.
Score: 0.034
-
Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for?Patients with Chronic Myelomonocytic Leukemia. Biol Blood Marrow Transplant. 2016 Jan; 22(1):47-53.
Score: 0.034
-
Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome. Leukemia. 2016 Feb; 30(2):325-30.
Score: 0.034
-
An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J. 2015 Jul 31; 5:e333.
Score: 0.034
-
Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome. Am J Hematol. 2015 Sep; 90(9):769-73.
Score: 0.034
-
Clonal evolution of acute myeloid leukemia relapsed after 19 years of remission. Am J Hematol. 2015 Jul; 90(7):E134-5.
Score: 0.034
-
TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis. Br J Haematol. 2015 Oct; 171(1):91-9.
Score: 0.034
-
Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion. Br J Haematol. 2016 Apr; 173(1):161-5.
Score: 0.034
-
Acute Myeloid Leukemia With t(v;5q33) Is Associated With Poor Overall Survival and Often Lacks Myelodysplastic Features. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15 Suppl:S85-90.
Score: 0.034
-
Comprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment. Leukemia. 2016 Jan; 30(1):242-7.
Score: 0.034
-
Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome. Cancer Cell. 2015 May 11; 27(5):644-57.
Score: 0.034
-
TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. J Hematol Oncol. 2015 May 08; 8:45.
Score: 0.034
-
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Am J Hematol. 2015 Apr; 90(4):276-81.
Score: 0.033
-
Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). Leukemia. 2015 Jul; 29(7):1502-13.
Score: 0.033
-
Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia. Br J Haematol. 2015 Aug; 170(4):590-3.
Score: 0.033
-
Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies. Clin Lymphoma Myeloma Leuk. 2015 Jul; 15(7):433-438.e2.
Score: 0.033
-
Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica. 2015 May; 100(5):653-61.
Score: 0.033
-
RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtype. Br J Haematol. 2015 May; 169(3):344-51.
Score: 0.033
-
Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytarabine. Biomed Res Int. 2015; 2015:497597.
Score: 0.033
-
Characteristics of Sweet Syndrome in patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15(6):358-363.
Score: 0.033
-
Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. Leuk Res. 2015 Mar; 39(3):348-54.
Score: 0.033
-
Very high levels of lactate dehydrogenase at diagnosis predict central nervous system relapse in acute promyelocytic leukaemia. Br J Haematol. 2015 May; 169(4):595-7.
Score: 0.033
-
Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2015 Feb; 90(2):120-4.
Score: 0.033
-
Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium. Cancer. 2015 Mar 15; 121(6):876-82.
Score: 0.033
-
Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide. Leuk Lymphoma. 2015 May; 56(5):1342-5.
Score: 0.032
-
Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experience. Am J Hematol. 2015 Jan; 90(1):27-30.
Score: 0.032
-
Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. Br J Haematol. 2015 Mar; 168(5):646-53.
Score: 0.032
-
A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Mar; 15(3):171-6.
Score: 0.032
-
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014 Oct 23; 124(17):2705-12.
Score: 0.032
-
Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes. Mod Pathol. 2015 Mar; 28(3):373-82.
Score: 0.032
-
Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Feb; 15(2):110-4.
Score: 0.032
-
A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2014 Oct; 14(5):401-10.
Score: 0.031
-
Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. Cancer. 2014 Jul 15; 120(14):2142-9.
Score: 0.031
-
Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure. Ther Adv Hematol. 2014 Apr; 5(2):29-34.
Score: 0.031
-
Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy. Am J Hematol. 2014 Apr; 89(4):395-8.
Score: 0.031
-
Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. Am J Hematol. 2014 Mar; 89(3):282-7.
Score: 0.031
-
BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS. Am J Hematol. 2014 May; 89(5):499-504.
Score: 0.031
-
Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents. Leuk Lymphoma. 2014 Aug; 55(8):1925-9.
Score: 0.031
-
Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):163-71.
Score: 0.031
-
Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy. Leukemia. 2014 Apr; 28(4):958-61.
Score: 0.031
-
Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):155-162.e1.
Score: 0.030
-
Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations. Leuk Lymphoma. 2014 Jun; 55(6):1431-4.
Score: 0.030
-
Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse. Leuk Lymphoma. 2014 Jun; 55(6):1337-44.
Score: 0.030
-
Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials. Clin Lymphoma Myeloma Leuk. 2013 Dec; 13(6):693-9.
Score: 0.030
-
Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol. 2013 Dec; 88(12):1024-9.
Score: 0.030
-
Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience. Leuk Lymphoma. 2014 Dec; 55(12):2879-86.
Score: 0.030
-
Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients =60 years with newly diagnosed acute myeloid leukemia. Am J Hematol. 2013 Nov; 88(11):961-6.
Score: 0.030
-
Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk. 2013 Sep; 13 Suppl 2:S289-94.
Score: 0.030
-
Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Sep; 13 Suppl 2:S276-81.
Score: 0.030
-
Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies. Leuk Res. 2013 Nov; 37(11):1461-7.
Score: 0.030
-
Impact of aberrant DNA methylation patterns including CYP1B1 methylation in adolescents and young adults with acute lymphocytic leukemia. Am J Hematol. 2013 Sep; 88(9):784-9.
Score: 0.030
-
MYBL2 is a sub-haploinsufficient tumor suppressor gene in myeloid malignancy. Elife. 2013 Jul 16; 2:e00825.
Score: 0.030
-
Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):477-84.
Score: 0.029
-
Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):435-40.
Score: 0.029
-
NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes. Leukemia. 2013 Oct; 27(10):2077-81.
Score: 0.029
-
A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome. Eur J Cancer Care (Engl). 2013 Sep; 22(5):605-11.
Score: 0.029
-
Low frequency of H3.3 mutations and upregulated DAXX expression in MDS. Blood. 2013 May 09; 121(19):4009-11.
Score: 0.029
-
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2013 Jun 06; 121(23):4655-62.
Score: 0.029
-
Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD. Br J Haematol. 2013 Jun; 161(5):659-666.
Score: 0.029
-
Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. Am J Hematol. 2013 May; 88(5):365-9.
Score: 0.029
-
Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study. Am J Hematol. 2013 Mar; 88(3):198-200.
Score: 0.029
-
The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):302-6.
Score: 0.029
-
Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):139-43.
Score: 0.029
-
Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation. Leukemia. 2013 Apr; 27(4):836-42.
Score: 0.028
-
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood. 2012 Dec 06; 120(24):4840-5.
Score: 0.028
-
Randomized, dose-escalation study of the p38a MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome. Leukemia. 2013 Apr; 27(4):977-80.
Score: 0.028
-
Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies. Haematologica. 2013 Feb; 98(2):217-21.
Score: 0.028
-
Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2012 Sep 20; 30(27):3376-82.
Score: 0.028
-
Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012 Sep 20; 120(12):2454-65.
Score: 0.028
-
A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. Leukemia. 2012 Nov; 26(11):2428-31.
Score: 0.027
-
Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS. Cancer. 2012 Nov 15; 118(22):5550-9.
Score: 0.027
-
Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol. 2012 May; 157(3):312-20.
Score: 0.027
-
Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system. Cancer. 2012 Sep 15; 118(18):4462-70.
Score: 0.027
-
Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response? J Clin Oncol. 2011 Nov 10; 29(32):4260-5.
Score: 0.026
-
Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol. 2011 Nov 01; 29(31):4088-95.
Score: 0.026
-
The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood. 2011 Oct 27; 118(17):4541-6; quiz 4759.
Score: 0.026
-
Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011 Jun 30; 364(26):2496-506.
Score: 0.026
-
Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation. J Clin Oncol. 2011 Jun 20; 29(18):2507-13.
Score: 0.025
-
Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. J Clin Oncol. 2011 Jun 01; 29(16):2240-6.
Score: 0.025
-
Pharmacokinetic evaluation of decitabine for the treatment of leukemia. Expert Opin Drug Metab Toxicol. 2011 May; 7(5):661-72.
Score: 0.025
-
Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol. 2011 May 20; 29(15):1963-70.
Score: 0.025
-
Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome. BMC Med Genet. 2010 Nov 16; 11:163.
Score: 0.025
-
Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. Blood. 2011 Feb 10; 117(6):1822-7.
Score: 0.025
-
A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2011 Mar 15; 117(6):1236-44.
Score: 0.025
-
Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor. Cancer. 2011 Feb 01; 117(3):572-80.
Score: 0.024
-
Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. Cancer. 2011 Jan 01; 117(1):110-5.
Score: 0.024
-
Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. Leuk Lymphoma. 2010 Aug; 51(8):1478-84.
Score: 0.024
-
Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. Br J Haematol. 2010 Aug; 150(3):303-12.
Score: 0.024
-
Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer. 2010 Jun 01; 116(11):2673-81.
Score: 0.024
-
Feasibility of therapy with hypomethylating agents in patients with renal insufficiency. Clin Lymphoma Myeloma Leuk. 2010 Jun; 10(3):205-10.
Score: 0.024
-
Acute myeloid leukemia with t(9;11)(p21-22;q23): common properties of dysregulated ras pathway signaling and genomic progression characterize de novo and therapy-related cases. Am J Clin Pathol. 2010 May; 133(5):686-93.
Score: 0.024
-
Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features. Leukemia. 2010 Apr; 24(4):740-7.
Score: 0.023
-
Decitabine in the treatment of myelodysplastic syndromes. Expert Rev Anticancer Ther. 2010 Jan; 10(1):9-22.
Score: 0.023
-
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood. 2010 Feb 11; 115(6):1131-6.
Score: 0.023
-
Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia. Cancer. 2009 Dec 01; 115(23):5490-8.
Score: 0.023
-
Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). Br J Haematol. 2010 Feb; 148(3):386-93.
Score: 0.023
-
Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. Leuk Res. 2010 Jun; 34(6):752-6.
Score: 0.023
-
Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis. Cancer. 2009 Oct 15; 115(20):4737-44.
Score: 0.023
-
Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution. Leukemia. 2009 Dec; 23(12):2275-80.
Score: 0.023
-
Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer. 2009 Aug 15; 115(16):3709-18.
Score: 0.023
-
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009 Jul 02; 114(1):144-7.
Score: 0.022
-
Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer. 2009 May 01; 115(9):1899-905.
Score: 0.022
-
Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia. 2009 Sep; 23(9):1605-13.
Score: 0.022
-
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet. 2009 Apr; 41(4):455-9.
Score: 0.022
-
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood. 2009 May 21; 113(21):5058-63.
Score: 0.022
-
Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome. Leukemia. 2009 Jul; 23(7):1297-302.
Score: 0.022
-
Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol. 2009 Apr 01; 27(10):1637-43.
Score: 0.022
-
Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant. 2009 Jun; 43(11):839-43.
Score: 0.022
-
Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens. Cancer. 2009 Jan 01; 115(1):101-6.
Score: 0.022
-
Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood. 2009 Mar 05; 113(10):2154-60.
Score: 0.022
-
Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival. Cancer. 2008 Dec 01; 113(11):3181-5.
Score: 0.022
-
Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status. Leuk Res. 2009 Jun; 33(6):837-9.
Score: 0.021
-
Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia. J Hematop. 2009 Mar; 2(1):2-8.
Score: 0.021
-
Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood. 2008 Dec 15; 112(13):4839-42.
Score: 0.021
-
The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer. 2008 Sep 15; 113(6):1338-43.
Score: 0.021
-
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood. 2008 Aug 01; 112(3):516-8.
Score: 0.021
-
Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies. Leukemia. 2008 Jun; 22(6):1117-24.
Score: 0.021
-
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood. 2008 Jul 01; 112(1):53-5.
Score: 0.021
-
Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia. Leuk Res. 2008 Oct; 32(10):1505-9.
Score: 0.021
-
A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Leukemia. 2008 May; 22(5):965-70.
Score: 0.021
-
Relapse and death during first remission in acute myeloid leukemia. Haematologica. 2008 Apr; 93(4):633-4.
Score: 0.021
-
MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications. Leukemia. 2008 Jun; 22(6):1095-105.
Score: 0.020
-
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2008 Jan 10; 26(2):196-203.
Score: 0.020
-
Potential cure of acute myeloid leukemia : analysis of 1069 consecutive patients in first complete remission. Cancer. 2007 Dec 15; 110(12):2756-60.
Score: 0.020
-
Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure. Cancer. 2007 Nov 01; 110(9):2000-6.
Score: 0.020
-
PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer. 2007 Nov 01; 110(9):2012-8.
Score: 0.020
-
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood. 2007 Dec 01; 110(12):4005-11.
Score: 0.020
-
Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood. 2007 Oct 15; 110(8):2991-5.
Score: 0.020
-
Biphenotypic acute leukaemia: a case series. Br J Haematol. 2007 Jul; 138(2):213-6.
Score: 0.020
-
Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome. Br J Haematol. 2007 Aug; 138(4):555-7.
Score: 0.019
-
Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer. 2007 Apr 01; 109(7):1355-9.
Score: 0.019
-
RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis. Cancer Res. 2007 Mar 01; 67(5):1997-2005.
Score: 0.019
-
Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer. 2007 Mar 01; 109(5):899-906.
Score: 0.019
-
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood. 2007 Jun 01; 109(11):4679-85.
Score: 0.019
-
Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood. 2007 Apr 15; 109(8):3214-8.
Score: 0.019
-
HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. Mod Pathol. 2007 Jan; 20(1):54-62.
Score: 0.019
-
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2006 Aug 01; 12(15):4628-35.
Score: 0.018
-
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia. 2006 Oct; 20(10):1767-73.
Score: 0.018
-
Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer. 2006 Jul 01; 107(1):125-35.
Score: 0.018
-
Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood. 2006 Oct 15; 108(8):2811-3.
Score: 0.018
-
DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. Cancer Res. 2006 May 15; 66(10):5495-503.
Score: 0.018
-
Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer. 2006 Jan 15; 106(2):346-52.
Score: 0.018
-
A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer. 2006 Jan 15; 106(2):337-45.
Score: 0.018
-
T-cell prolymphocytic leukemia: a single-institution experience. Clin Lymphoma Myeloma. 2005 Nov; 6(3):234-9.
Score: 0.017
-
Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood. 2006 Jan 15; 107(2):480-2.
Score: 0.017
-
Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2005 Sep 15; 11(18):6615-24.
Score: 0.017
-
Cardiotoxicity in African-American patients treated with arsenic trioxide for acute promyelocytic leukemia. Leuk Res. 2006 Mar; 30(3):362-3.
Score: 0.017
-
2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer. 2005 Aug 01; 104(3):541-6.
Score: 0.017
-
Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986. Cancer. 2005 Jun 15; 103(12):2551-7.
Score: 0.017
-
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. Leuk Res. 2005 Jun; 29(6):649-52.
Score: 0.017
-
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 20; 23(18):4070-8.
Score: 0.017
-
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood. 2005 Mar 15; 105(6):2281-6.
Score: 0.016
-
Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience. Am J Hematol. 2004 Nov; 77(3):209-14.
Score: 0.016
-
Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. Cancer. 2004 Jun 15; 100(12):2592-7.
Score: 0.016
-
C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome. Leuk Res. 2004 Apr; 28(4):373-8.
Score: 0.016
-
Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haematol. 2004 Apr; 125(2):187-95.
Score: 0.016
-
Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer. 2004 Feb 01; 100(3):581-9.
Score: 0.015
-
Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 1):88-95.
Score: 0.015
-
DNA methylation in haematological malignancies: the role of decitabine. Expert Opin Investig Drugs. 2003 Dec; 12(12):1985-93.
Score: 0.015
-
Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leuk Res. 2003 Dec; 27(12):1077-83.
Score: 0.015
-
Comment on "Chromosomal instability and tumors promoted by DNA hypomethylation" and "Induction of tumors in nice by genomic hypomethylation". Science. 2003 Nov 14; 302(5648):1153; author reply 1153.
Score: 0.015
-
Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer. 2003 Nov 01; 98(9):1905-11.
Score: 0.015
-
Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leuk Res. 2003 Oct; 27(10):893-7.
Score: 0.015
-
Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. Cancer Chemother Pharmacol. 2003 Dec; 52(6):449-52.
Score: 0.015
-
Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy. Leukemia. 2003 Jun; 17(6):1100-3.
Score: 0.015
-
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J Clin Oncol. 2003 May 01; 21(9):1722-7.
Score: 0.015
-
Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases. Cancer. 2003 Apr 15; 97(8):1920-8.
Score: 0.015
-
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer. 2003 Apr 01; 97(7):1711-20.
Score: 0.015
-
Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia. Leuk Res. 2003 Apr; 27(4):301-4.
Score: 0.015
-
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer. 2003 Mar 15; 97(6):1481-7.
Score: 0.014
-
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2003 Mar 01; 97(5):1234-41.
Score: 0.014
-
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood. 2003 May 01; 101(9):3413-5.
Score: 0.014
-
Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemother Pharmacol. 2003 Jan; 51(1):87-90.
Score: 0.014
-
Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy. Haematologica. 2002 Oct; 87(10):1114-6.
Score: 0.014
-
Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia. 2002 Jun; 16(6):1045-52.
Score: 0.014
-
Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course. Cancer. 2002 May 01; 94(9):2416-25.
Score: 0.014
-
Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 2001 Jul 15; 92(2):406-13.
Score: 0.013